Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 131Gastrointestinal Stromal Tumors 67Leukemia 66Leukemia, Myeloid, Chronic-Phase 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Blast Crisis 22Brain Neoplasms 15Philadelphia Chromosome 14Melanoma 13Sarcoma 12Neoplasms 12Neoplasm Metastasis 12Leukemia, Myeloid, Acute 12Leukemia, Myeloid, Accelerated Phase 12Glioblastoma 12Lung Neoplasms 11Prostatic Neoplasms 10Leukemia, Myeloid 9Gliosarcoma 9Glioma 8Breast Neoplasms 8Primary Myelofibrosis 7Leukemia, Myelomonocytic, Chronic 7Central Nervous System Neoplasms 7Astrocytoma 7Recurrence 6Polycythemia Vera 6Ovarian Neoplasms 6Oligodendroglioma 6Myeloproliferative Disorders 6

Interventions

pazopanib 2Proton Therapy 2Ifosfamide 2Doxorubicin 2tazemetostat 1selinexor 1pirfenidone 1Zoledronic Acid 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Protons 1Nivolumab 1Neurofibromin 1 1Ipilimumab 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Nerve Sheath Neoplasms × Imatinib Mesylate × Clear all
NCT00427583 2012-08-07

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Novartis

Phase 2/3 Terminated
11 enrolled
CNSSarcoma

Neurofibromatoses, Nerve Sheath Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡